These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8105846)

  • 1. Immunotoxin therapy of lymphoma.
    Grossbard ML; Nadler LM
    Cancer Treat Res; 1993; 68():111-31. PubMed ID: 8105846
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins.
    Frankel AE; FitzGerald D; Siegall C; Press OW
    Cancer Res; 1996 Feb; 56(4):926-32. PubMed ID: 8631036
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotoxin therapy of malignant melanoma.
    Spitler LE
    Med Oncol Tumor Pharmacother; 1986; 3(3-4):147-52. PubMed ID: 3543527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-based therapies of leukemia and lymphoma.
    Grossbard ML; Press OW; Appelbaum FR; Bernstein ID; Nadler LM
    Blood; 1992 Aug; 80(4):863-78. PubMed ID: 1498329
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibodies in the study and therapy of hematopoietic cancers.
    Matthews DC; Smith FO; Bernstein ID
    Curr Opin Immunol; 1992 Oct; 4(5):641-6. PubMed ID: 1418732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotoxin therapy of lymphoid neoplasms.
    Grossbard ML; Nadler LM
    Semin Hematol; 1994 Jan; 31(1):88-97. PubMed ID: 8122137
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted therapy for hematologic malignancies: has its promise been realized?
    Matthews DC; Appelbaum FR; Press OW; Eary JF; Bernstein ID
    Curr Opin Hematol; 1995 Jul; 2(4):235-9. PubMed ID: 9372002
    [No Abstract]   [Full Text] [Related]  

  • 8. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers.
    Scheinberg DA
    Curr Opin Immunol; 1991 Oct; 3(5):679-84. PubMed ID: 1661602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Adv Nephrol Necker Hosp; 1994; 23():347-56. PubMed ID: 8154364
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotoxins in the therapy of leukemias and lymphomas.
    Hertler AA; Frankel AE
    Cancer Invest; 1991; 9(2):211-9. PubMed ID: 1863876
    [No Abstract]   [Full Text] [Related]  

  • 11. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific destruction of allogeneic tumor cells in vivo by a bismuth-212 immunotoxin.
    Stuart FP; Perdrizet G; Steranka B; Buckingham M; Lopes D; Alvarez V; Rodwell J; McKearn T; Hines J; Atcher R
    Transplant Proc; 1987 Feb; 19(1 Pt 1):605-6. PubMed ID: 3274825
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotoxins for treatment of leukemia and lymphoma.
    Uckun FM; Reaman GH
    Leuk Lymphoma; 1995 Jul; 18(3-4):195-201. PubMed ID: 8535182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxins in the therapy of cancer: from bench to clinic.
    Ghetie V; Vitetta E
    Pharmacol Ther; 1994 Sep; 63(3):209-34. PubMed ID: 7831391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxin therapy of leptomeningeal neoplasia.
    Walbridge S; Rybak SM
    J Neurooncol; 1994; 20(1):59-65. PubMed ID: 7807185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
    Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
    Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma.
    Foon KA; Schroff RW; Bunn PA
    Prog Clin Biol Res; 1986; 211():265-84. PubMed ID: 3515361
    [No Abstract]   [Full Text] [Related]  

  • 18. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
    Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
    Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy of lymphomas and leukemia.
    Kaminski MS; Foon KA
    Cancer Treat Res; 1988; 38():253-63. PubMed ID: 2908598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.